We use our libraries of fully human IgGs expressed in yeast to put antibodies into your hands quickly.
We improve and refine lead antibodies to turn good molecules into best-in-class molecules.
We offer a variety of bispecific formats that cover a wide range of biological functionality.
Using our proprietary platform we discover therapeutic antibodies that meet the highest standards of quality and developability.
We provide a full implementation of the Adimab Platform to enable your scientists to discover and optimize lead candidates within your existing workflow.
Board of Directors
News & Press Releases